Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDA SOUTH SAN FRANCISCO, Calif.
, Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA ), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B.
Snyder , joined the company as its Senior Vice President, General Counsel on September 18, 2024 . "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharmaceuticals and the FDA. He has developed extensive commercial and international experience across multiple organizations that makes him well-equipped to lead IDEAYA's legal functions as we continue to build a leading global precision medicine oncology company," said Yujiro S.
Hata , President and Chief Executive Officer of IDEAYA Biosciences. "I am excited to join IDEAYA during this exciting growth phase as the company prepares for potential commercialization of Darovasertib and broadens its clinical pipeline efforts, including in MTAP-deletion. I look forward to partnering with the management team and the broader organization to advance our collective mission to deliver transformative precision medicines to cancer patients," said Douglas B.
Snyder . Mr. Snyder most recently served as Executive Vice President, Chief Legal Officer and Secretary at GW Pharmaceuticals (NASDAQ: GWPH ) from 2017 to 2022.